GlaxoSmithKline (GSK) has announced plans to invest $1.2 billion which includes a new biologics “flex factory” at its Upper Merion site in Montgomery County, part of its broader $30 billion U.S. investment strategy over the next five years. With this latest commitment, GSK has now pledged nearly $2 billion in Pennsylvania alone, following last year’s $800 million expansion at its Marietta facility in Lancaster County.
(GSK)
$1.2 Billion Upper Merion Biologics Facility
According to GSK, the Upper Merion project will create a next-generation biologics flex factory, designed to produce treatments for respiratory diseases such as COPD and asthma, as well as cancer therapies. Construction is scheduled to begin in 2026. The investment also includes new AI and advanced digital upgrades across GSK’s U.S. sites, including Pennsylvania.
The company stated that the new projects will “create hundreds of highly skilled jobs (in addition to construction jobs).” (GSK)
Building on $800 Million in Lancaster County
This announcement follows GSK’s October 2024 decision to invest up to $800 million at its Marietta site in Lancaster County — the company’s largest U.S. manufacturing investment to date. That project will double the size and capacity of the facility, expanding drug substance and vaccine production.
(GSK US)
The Commonwealth supported the Lancaster County expansion with $21 million in incentives, which Governor Josh Shapiro described as – “The largest Commonwealth-supported economic development project in Lancaster County history.” (PA.gov).
“Pennsylvania is a leader in life sciences – and GSK’s decision to make its largest single investment ever in manufacturing in the United States right here in the Commonwealth is further proof that we are the best state in the nation for business growth and economic development.” (PA.gov)
The Marietta expansion is expected to create more than 200 new jobs and retain 4,622 existing roles across Pennsylvania. State officials noted the site’s national importance, with “one in four Americans administered a vaccine supplied from the company’s Marietta location.” (PACast)
With billions now committed, thousands of jobs retained, and hundreds more on the way, the company’s investment signals long-term confidence in the Commonwealth’s talent, infrastructure, and leadership.
Pennsylvania’s Biopharma Manufacturing Belt
Together, Lancaster and Montgomery Counties form a powerful biopharma manufacturing belt that anchors Pennsylvania’s role in the U.S. life sciences industry. Alongside GSK, several other global companies have major operations in the region:
- Merck (West Point, Montgomery County): Merck’s West Point site is its largest U.S. pharmaceutical manufacturing campus, employing thousands in vaccine and drug production. (Montco.Today)
- Johnson & Johnson (Fort Washington & Spring House, Montgomery County): J&J operates a Fort Washington manufacturing plant and a Janssen R&D campus in Spring House, with additional offices in Horsham. (Montco.Today)
- Eurofins Lancaster Laboratories (Lancaster County): One of the world’s largest contract labs for biopharma testing and analytics, serving global clients from its Lancaster base. (Eurofins)
- Almac Group (Souderton, Montgomery County): The company’s U.S. headquarters supports drug development and clinical trials, with a $65 million expansion underway. (Pharmaceutical Technology)
- Nucleus RadioPharma (Lower Gwynedd, Montgomery County): Announced a new 48,000 sq. ft. radiopharmaceutical manufacturing facility in 2024, backed by AstraZeneca. (Patch)
This cluster of established operations, combined with GSK’s new $2 billion commitment, positions Pennsylvania as a national leader in advanced manufacturing, vaccines, and biologics.
From Lancaster’s vaccine powerhouse to Montgomery County’s biologics innovation hub, Pennsylvania is attracting sustained investment from the world’s largest pharmaceutical companies. For the Commonwealth, the payoff is clear: thousands of jobs retained, hundreds more being created, and a growing reputation as one of America’s premier life sciences regions.
